| Non-Small Cell Lung Carcinoma

Keytruda vs Tagrisso

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Keytruda vs Tagrisso with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTagrisso has a higher rate of injection site reactions vs Keytruda based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tagrisso but not Keytruda, including UnitedHealthcare

Category

Keytruda

Tagrisso

At A Glance

RouteIV infusion

FrequencyEvery 3 weeks or Every 6 weeks

ClassPD-1 inhibitor

RouteOral

FrequencyDaily

ClassEGFR kinase inhibitor

Indications

melanoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of the head and neck
Classic Hodgkin Lymphoma
Mediastinal (Thymic) Large B-Cell Lymphoma
Urothelial Carcinoma
Colorectal Carcinoma
Stomach Carcinoma
Esophageal carcinoma
Cervix carcinoma
Liver carcinoma
Biliary Tract Cancer
Merkel cell carcinoma
Renal Cell Carcinoma
Endometrial Carcinoma
Triple-Negative Breast Carcinoma
Malignant neoplasm of ovary
Squamous cell carcinoma of skin

Non-Small Cell Lung Carcinoma

Dosing

melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV

Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV

Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily

Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors

Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV

Adjuvant Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease recurrence, unacceptable toxicity, or for up to 3 years.

Locally advanced, unresectable (Stage III) Non-Small Cell Lung Carcinoma Following platinum-based chemoradiation therapy, 80 mg orally once daily until disease progression or unacceptable toxicity.

First-line metastatic Non-Small Cell Lung Carcinoma (monotherapy) 80 mg orally once daily until disease progression or unacceptable toxicity.

First-line locally advanced or metastatic Non-Small Cell Lung Carcinoma (combination) 80 mg orally once daily in combination with pemetrexed and platinum-based chemotherapy until disease progression or unacceptable toxicity.

Previously treated EGFR T790M mutation-positive metastatic Non-Small Cell Lung Carcinoma 80 mg orally once daily until disease progression or unacceptable toxicity.

Contraindications

—

Drug Interactions

188View drug interactions

1081View drug interactions

Adverse Reactions

Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism

Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions

Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis

Most common (>=20%) Diarrhea, rash, musculoskeletal pain, nail toxicity, dry skin, stomatitis, fatigue.

Serious ILD/pneumonitis, QTc interval prolongation, cardiomyopathy, keratitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, aplastic anemia.

Postmarketing Erythema multiforme major, Stevens-Johnson syndrome, toxic epidermal necrolysis, cutaneous vasculitis, erythema dyschromicum perstans, aplastic anemia.

Pharmacology

Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.

Osimertinib is a kinase inhibitor that irreversibly binds to mutant EGFR forms (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type EGFR, inhibiting tumor cell proliferation in EGFR mutation-positive NSCLC; it also inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Keytruda